Get started
Author

Fabio Cury

Observed names: F Cury, F. Cury, F. L. Cury, F.L. Cury, F.L.B. Cury, Fabio L Cury, Fabio L. Cury, Fabio L.B. Cury, Fabio LB Cury
Observed institutions: Montreal General Hospital, McGill University Health Centre, Hôtel-Dieu de Québec, Prostate Cancer Canada, Research Institute of the McGill University Health Centre, McGill University, Université de Montréal
ORCID: 0000-0003-1293-0822
Observed ORCID: 0000-0003-1293-0822
OpenAlex ID: A5091337701
NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer
2020 · William A. Hall, Eric Paulson, et al. · International Journal of Radiation Oncology*Biology*Physics · 161
5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney)
2022 · Shankar Siva, Muhammad Ali, et al. · The Lancet Oncology · 149
Brachytherapy Improves Biochemical Failure–Free Survival in Low- and Intermediate-Risk Prostate Cancer Compared With Conventionally Fractionated External Beam Radiation Therapy: A Propensity Score Matched Analysis
2015 · Graham D. Smith, Tom Pickles, et al. · International Journal of Radiation Oncology*Biology*Physics · 77
Hypofractionated Intensity Modulated Radiation Therapy in Combined Modality Treatment for Bladder Preservation in Elderly Patients With Invasive Bladder Cancer
2014 · Guy-Anne Turgeon, Luis Souhami, et al. · International Journal of Radiation Oncology*Biology*Physics · 77
The Role of HMGB1 in Radioresistance of Bladder Cancer
2015 · Sanhita Shrivastava, Jose Joao Mansure, et al. · Molecular Cancer Therapeutics · 75
Combined radiotherapy and immunotherapy in urothelial bladder cancer: harnessing the full potential of the anti-tumor immune response
2020 · Mame Daro-Faye, Wassim Kassouf, et al. · World Journal of Urology · 62
PDF
Ultrasound-based image guided radiotherapy for prostate cancer—comparison of cross-modality and intramodality methods for daily localization during external beam radiotherapy
2006 · Fabio L.B. Cury, George Shenouda, et al. · International Journal of Radiation Oncology*Biology*Physics · 61
Practical considerations for prostate hypofractionation in the developing world
2021 · Michael Yan, Andre G. Gouveia, et al. · Nature Reviews Urology · 50
PDF
Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial
2023 · Daniel J. Krauss, Theodore Karrison, et al. · Journal of Clinical Oncology · 46
PDF
Phase 1 Trial of Atezolizumab Plus Trimodal Therapy in Patients With Localized Muscle-Invasive Bladder Cancer
2021 · Gautier Marcq, Luis Souhami, et al. · International Journal of Radiation Oncology*Biology*Physics · 42
Combining Radiation Therapy and Androgen Deprivation for Localized Prostate Cancer—A Critical Review
2010 · A. Dal Pra, F. L. Cury, et al. · Current Oncology · 42
PDF
Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
2010 · Nicholas Rene, Sergio Faria, et al. · International Journal of Radiation Oncology*Biology*Physics · 41
Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trial
2025 · Tamim Niazi, Fred Saad, et al. · The Lancet Oncology · 38
Drug costs in the management of metastatic castration-resistant prostate cancer in Canada
2014 · Alice Dragomir, Daniela Dinea, et al. · BMC Health Services Research · 38
PDF
The prostate cancer risk stratification (ProCaRS) project: Recursive partitioning risk stratification analysis
2013 · George Rodrigues, Himu Lukka, et al. · Radiotherapy and Oncology · 35
Improving ultrasound-based prostate volume estimation
2019 · Saro Aprikian, Murilo Luz, et al. · BMC Urology · 34
PDF
Abscopal Effect in a Stage IV Melanoma Patient who Progressed on Pembrolizumab
2018 · James M Tsui, Catalin Mihalcioiu, et al. · Cureus · 34
PDF
Stereotactic Fractionated Radiotherapy in the Treatment of Juxtapapillary Choroidal Melanoma: The McGill University Experience
2011 · Rolina Al-Wassia, Alan Dal Pra, et al. · International Journal of Radiation Oncology*Biology*Physics · 32
Benefit of Neoadjuvant Cisplatin-based Chemotherapy for Invasive Bladder Cancer Patients Treated with Radiation-based Therapy in a Real-world Setting: An Inverse Probability Treatment Weighted Analysis
2024 · Ronald Kool, Alice Dragomir, et al. · European Urology Oncology · 30
Sci—Thur AM: YIS ‐ 02: Radiogenomic Modeling of Normal Tissue Toxicities in Prostate Cancer Patients Receiving Hypofractionated Radiotherapy
2014 · J Coates, K Jeyaseelan, et al. · Medical Physics · 30
Contrasting analytical and data-driven frameworks for radiogenomic modeling of normal tissue toxicities in prostate cancer
2015 · James Coates, Asha K. Jeyaseelan, et al. · Radiotherapy and Oncology · 29
Combining mTOR Inhibition with Radiation Improves Antitumor Activity in Bladder Cancer Cells In Vitro and In Vivo: A Novel Strategy for Treatment
2013 · Roland Nassim, Jose Joao Mansure, et al. · PLoS ONE · 29
PDF
Hypofractionated Radiation Therapy (66 Gy in 22 Fractions at 3 Gy per Fraction) for Favorable-Risk Prostate Cancer: Long-term Outcomes
2013 · Nita Patel, Sergio Faria, et al. · International Journal of Radiation Oncology*Biology*Physics · 29
Management of localized and advanced prostate cancer in Canada: A lifetime cost and quality‐adjusted life‐year analysis
2016 · Chiranjeev Sanyal, Armen G. Aprikian, et al. · Cancer · 28
PDF
Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926
2024 · Douglas M. Dahl, Joseph P. Rodgers, et al. · Journal of Clinical Oncology · 27
PDF
Works count: 237
Citation count: 2,113
H-index: 26
I10-index: 66
Year
Topic
Type